pocketful logo
Bal Pharma Ltd logo

Bal Pharma Ltd

NSE: BALPHARMA BSE: 524824

₹64.87

(7.37%)

Thu, 02 Apr 2026, 00:17 pm

mtf coin illustrationMTF 5x

Bal Pharma Share Price Live Chart

1 Day

0 (0%)

No Result Found

Summary

  • Market Cap

    103.49

  • Net Profit

    7.24

  • P/B

    1.71

  • Sector P/E

    31.44

  • P/E

    18.36

  • EV/EBITDA

    8.60

  • Debt/Equity (Industry)

    0.23

  • Interest Cover (Industry)

    9.71

  • ROCE (Industry)

    13

  • RONW (Industry)

    12.31

  • ROE

    9.69

  • ROCE

    9.78

  • Debt/Equity

    1.94

  • EPS (TTM)

    5.10

  • Dividend Yield

    1.85

  • Book Value

    49.20

  • Interest Cover

    1.30

Analysis

all

thumbs up icon

Pros

  • Dividends per share have increased over the past 10 years.
  • Bal Pharma's pays a higher dividend yield than the bottom 25% of dividend payers in India (0.76%).
  • Bal Pharma is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Bal Pharma has been profitable on average in the past, therefore cash runway is not a concern.
  • Bal Pharma has been profitable on average in the past, therefore cash runway is not a concern.
thumbs up icon

Cons

  • The company is paying a dividend however it is incurring a loss.
  • Dividends per share have been volatile in the past 10 years (annual drop of over 20%).
  • Bal Pharma's dividend is below the markets top 25% of dividend payers in India (3.08%).
  • Debt is not well covered by operating cash flow (6.8%, less than 20% of total debt).
  • The level of debt compared to net worth has increased over the past 5 years (85.7% vs 205.1% today).

Read More

Financials

No Result Found

Read More

Ratios

No Result Found

Read More

Shareholding

ShareholdersDEC 2025SEPT 2025JUN 2025MAR 2025DEC 2024
Promoters50.8650.8650.8650.8650.86
FII0.140.220.150.140.14
DII00000
Public49.0148.9248.9949.0049.00
Government00000

Read More

Technical Analysis

RSI

-

MACD

-

50 DMA

-

200 DMA

-

Support and Resistance

TypeR3R2R1PPS1S2S3
Classic-------
Fibonacci-------
Camarilla-------

Pivots Level: Classic

R3

+-

-

R2

+-

-

R1

+-

-

-
-
Pivot Point
LTP: -

S1

--

-

S2

--

-

S3

--

-

Moving Average

SMAEMA

Period

Value

  • 10-EMA

    -

  • 20-EMA

    -

  • 30-EMA

    -

  • 50-EMA

    -

  • 100-EMA

    -

  • 200-EMA

    -

Read More

Corporate Actions

Announcement DatePurposeActionEx Date
11 Feb 2026board-meetingsQuarterly Results
18 Aug 2025dividendDividend - Rs. - 1.218 Sept 2025
11 Aug 2025agm
29 May 2025dividend₹1.20 Dividend /Share18 Sept 2025
17 Aug 2024dividendAnnual General Me0etingdividend - Rs 1.2 Per Share19 Sept 2024
14 Aug 2024agm
28 May 2024dividend₹1.20 Dividend /Share19 Sept 2024
20 Nov 2023egm
31 Aug 2023egm
18 Aug 2023dividendAnnual General Meeting/Dividend - Re 1 Per Share19 Sept 2023

Read More

Peer Comparison

No Result Found

Bal Pharma Ltd logo

Bal Pharma Ltd

Lupin Ltd logo

Lupin Ltd

Divis Laboratories Ltd logo

Divis Laboratories Ltd

Dr Reddys Laboratories Ltd logo

Dr Reddys Laboratories Ltd

Torrent Pharmaceuticals Ltd logo

Torrent Pharmaceuticals Ltd

Sun Pharmaceutical Industries Ltd logo

Sun Pharmaceutical Industries Ltd

Read More

Bal Pharma Ltd About

Bal Pharma is engaged in the manufacturing and selling of pharmaceutical products. The Company caters to both domestic and international markets.

Industry

Pharmaceuticals - Indian - Bulk Drugs & Formln

Founded

1987

Headquarters

CEO

Employees

Contact

Website icon

Website

http://www.balpharma.com

Email icon

Email

investor@balpharma.com

Phone icon

Phone

Location icon

Location

21 & 22 Bommasandra Indl Area, Hosur Road, Bangalore, Karnataka, 560092

Read More

Bal Pharma Ltd Company History

YearHistory
2014
  • Bal Pharma recommended payment of a dividend of Re. 1/- (10%) per Equity Share of Rs. 10 each.
2015
  • Bal Pharma Ltd ventured into the OTC Segment.
2021
  • Bal Pharma Ltd launched the antiviral drug Favipiravir in the domestic market under the brand name BAL flu for the treatment of COVID-19.
  • Mr. Shailesh Siroya acquired 650,000 equity shares of the Company.
2023
  • NCLT gave approval for the merger of Golden Drugs Pvt Ltd with Bal Pharma Limited.
2024
  • The Company commenced the API green field project at Kadechur KIADB industrial Area, Yadgir District.

Read More

Deals

Client NameOrder SideQTYAvg PriceDate
NK SECURITIES RESEARCH PRIVATE LIMITEDSell132023121.1704 Apr 2025
PARTH INFIN BROKERS PVT LTDBuy110803125.3104 Apr 2025
PARTH INFIN BROKERS PVT LTDSell110803124.3604 Apr 2025
MUDUPULAVEMULA SURENDRANADHA REDDYSell123412121.5104 Apr 2025
NK SECURITIES RESEARCH PRIVATE LIMITEDBuy132023121.0304 Apr 2025
MUDUPULAVEMULA SURENDRANADHA REDDYBuy123412120.9604 Apr 2025
NK SECURITIES RESEARCH PRIVATE LIMITEDSell86838143.0723 Aug 2024
NK SECURITIES RESEARCH PRIVATE LIMITEDBuy86838142.8523 Aug 2024
NK SECURITIES RESEARCH PRIVATE LIMITEDBuy90349134.7422 Aug 2024
NK SECURITIES RESEARCH PRIVATE LIMITEDSell90349134.9322 Aug 2024

Read More

Bal Pharma Ltd News

Bal Pharma Q3FY26 Net Profit Surges 181.84% YoY

Bal Pharma Limited reported strong Q3FY26 results with net profit jumping 181.84% YoY to ₹194.62 lakhs. Revenue from operations grew 20.03% to ₹8,749.48 lakhs, driven by improved operational efficiency.

11 Feb 2026

co actions results

Bal Pharma Limited Reports Quarterly Results and Appoints New Independent Director

Bal Pharma Limited's Board approved unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025. The company reported standalone revenue from operations of Rs 7,470.00 lakhs for the quarter, with a net profit of Rs 80.18 lakhs. For the half year, revenue stood at Rs 13,908.84 lakhs with net profit of Rs 175.68 lakhs. The Board also appointed Dr. Bheekamchand Mukesh as an additional Non-executive Independent Director. Dr. Mukesh brings 35 years of experience in pharmaceutical research, development and commercialization. The statutory auditors issued an unmodified opinion on the financial results.

12 Nov 2025

earnings

Bal Pharma Defers Subsidiary Merger Decision Due to Inadequate Data

Bal Pharma Limited has deferred its decision on the proposed merger of its subsidiary Lifezen Healthcare Pvt Ltd with the company. The Board of Directors considered the merger proposal during their meeting but decided to postpone the matter due to inadequate data. The board has instructed management to re-present the proposal with all necessary details to enable an informed decision. The company had previously notified exchanges about including this merger proposal among the agenda items for the board meeting.

07 Nov 2025

corporate action

Bal Pharma Sets September 18, 2025 as Record Date for Dividend Payment

Bal Pharma Limited's Board of Directors has fixed September 18, 2025 as the record date for dividend payment for the financial year ended March 31, 2025. The dividend payment is subject to shareholder approval at the company's 38th Annual General Meeting scheduled for September 25, 2025. The board decision was made at their meeting held on August 11, 2025.

12 Aug 2025

corporate action

Bal Pharma Limited Approves Q1 FY2026 Results and Employee Stock Option Plan

Bal Pharma Limited's Board of Directors approved unaudited standalone and consolidated financial results for the quarter ended June 30, 2025. The company reported standalone revenue from operations of ₹6,563.51 lakhs and net profit of ₹32.31 lakhs for the quarter. On a consolidated basis, revenue from operations was ₹6,587.09 lakhs with net profit of ₹20.85 lakhs. The Board scheduled the 38th Annual General Meeting for September 25, 2025, and decided to close the register of members from September 19-25, 2025. Additionally, the Board approved an Employee Stock Option Plan-2025, subject to shareholder approval at the upcoming AGM. The company's statutory auditors issued an unmodified opinion on the quarterly results.

11 Aug 2025

earnings

Read More

Open Your Free Demat Account Now!

Step into a world of zero fees and limitless opportunities!

pocketful logo

2022-25 Pocketful. All rights reserved, Built with in India

Version -5.76

app image 1app image 2

Stocks:

AllABCDEFGHIJKLMNOPQRSTUVWXYZ

Explore

Calculatorsfooter arrow down icon
Popular Calculatorsfooter arrow down icon
Group Stocksfooter arrow down icon

Others:

NSEBSECDSLNSDLSEBIMCXMSEINCDEXNSE IFSCINDIA INXAccount Closure FormDP Investor CharterBroker Investor Charter

Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800